BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34115196)

  • 1. An immunohistochemical panel of insulin-like growth factor II mRNA-binding protein 3 (IMP3), enhancer of zeste homolog 2 (EZH2), and p53 is useful for a diagnosis in bile duct biopsy.
    Sasaki M; Sato Y
    Virchows Arch; 2021 Oct; 479(4):697-703. PubMed ID: 34115196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is a marker that predicts presence of invasion in papillary biliary tumors.
    Sasaki M; Sato Y
    Hum Pathol; 2017 Apr; 62():152-159. PubMed ID: 28089541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct.
    Sasaki M; Matsubara T; Yoneda N; Nomoto K; Tsuneyama K; Sato Y; Nakanuma Y
    Histopathology; 2013 Feb; 62(3):446-57. PubMed ID: 23163606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
    Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
    Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy.
    Levy M; Lin F; Xu H; Dhall D; Spaulding BO; Wang HL
    Hum Pathol; 2010 Sep; 41(9):1210-9. PubMed ID: 20382408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of IMP3, S100P, and pVHL immunopanel to aid in the interpretation of bile duct biopsies with atypical histology or suspicious for malignancy.
    Schmidt MT; Himmelfarb EA; Shafi H; Lin F; Xu H; Wang HL
    Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):478-87. PubMed ID: 22495381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2023 Aug; 83(2):298-309. PubMed ID: 37140546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
    Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic value of immunohistochemical expression of S100P and IMP3 in transpapillary biliary forceps biopsy samples of extrahepatic bile duct carcinoma.
    Kawashima H; Itoh A; Ohno E; Miyahara R; Ohmiya N; Tanaka T; Shimoyama Y; Nakamura S; Ebata T; Nagino M; Goto H; Hirooka Y
    J Hepatobiliary Pancreat Sci; 2013 Apr; 20(4):441-7. PubMed ID: 23269460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma.
    Chen YL; Jeng YM; Hsu HC; Lai HS; Lee PH; Lai PL; Yuan RH
    Int J Surg; 2013; 11(1):85-91. PubMed ID: 23246869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.
    Nakagawa S; Okabe H; Ouchi M; Tokunaga R; Umezaki N; Higashi T; Kaida T; Arima K; Kitano Y; Kuroki H; Mima K; Nitta H; Imai K; Hashimoto D; Yamashita YI; Chikamoto A; Baba H
    HPB (Oxford); 2018 Oct; 20(10):939-948. PubMed ID: 29759640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3.
    Tang B; Du J; Li Y; Tang F; Wang Z; He S
    Med Oncol; 2014 Nov; 31(11):271. PubMed ID: 25280519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
    Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
    Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of IMP3 and p53 in inflammatory lesions and neoplastic lesions of the gastric mucosa.
    Strehl JD; Hoegel J; Hornicek I; Hartmann A; Riener MO
    Int J Clin Exp Pathol; 2014; 7(5):2091-101. PubMed ID: 24966917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagy may occur at an early stage of cholangiocarcinogenesis via biliary intraepithelial neoplasia.
    Sasaki M; Nitta T; Sato Y; Nakanuma Y
    Hum Pathol; 2015 Feb; 46(2):202-9. PubMed ID: 25466963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions.
    Bertram S; Padden J; Kälsch J; Ahrens M; Pott L; Canbay A; Weber F; Fingas C; Hoffmann AC; Vietor A; Schlaak JF; Eisenacher M; Reis H; Sitek B; Baba HA
    J Clin Pathol; 2016 Jul; 69(7):619-26. PubMed ID: 26729014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm.
    Nakanishi Y; Zen Y; Kondo S; Itoh T; Itatsu K; Nakanuma Y
    Hum Pathol; 2008 Aug; 39(8):1153-61. PubMed ID: 18495210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas.
    Riener MO; Fritzsche FR; Clavien PA; Pestalozzi BC; Probst-Hensch N; Jochum W; Kristiansen G
    Hum Pathol; 2009 Oct; 40(10):1377-83. PubMed ID: 19467694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of maspin in distinguishing adenocarcinoma from benign biliary epithelium on endoscopic bile duct biopsy.
    Chen L; Huang K; Himmelfarb EA; Zhai J; Lai JP; Lin F; Wang HL
    Hum Pathol; 2015 Nov; 46(11):1647-54. PubMed ID: 26362203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.